Betamethasone Dipropionate IP 0.25 mg + Fusidic Acid IP 20 mg Chlorocresol lp 1.2 mg

Betamethasone Dipropionate IP 0.25 mg + Fusidic Acid IP 20 mg Chlorocresol lp 1.2 mg is a topical formulation formulated with Betamethasone Dipropionate IP 0.25 mg + Fusidic Acid IP 20 mg Chlorocresol lp 1.2 mg. The listed active ingredient profile is Betamethasone Dipropionate; Fusidic Acid Chlorocresol lp, placing the product in the topical anti-inflammatory / dermatology category. The formulation contains topical anti-inflammatory ingredient(s), including corticosteroid or immunomodulatory components, for selected inflammatory skin conditions. The dosage form is intended for topical/local application; the exact application site and frequency must follow the approved product instructions. For website cataloguing, the composition, strength, dosage form and formulation characteristics should be displayed prominently and consistently. The product description should remain factual and should not include unapproved cure, superiority, guaranteed-result or broad therapeutic claims. Clinical selection should depend on diagnosis, patient-specific factors, contraindications, concomitant medicines and professional judgement. Prescription status, warnings, interactions, adverse effects and dosing or application instructions must be checked against the current approved product label. Manufacturer, licence, storage, shelf-life, reconstitution where applicable, and market-specific regulatory details should be added only from verified product documentation.